Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Radiotherapy & Radiosurgery
Radioiodine therapy
Radioiodine therapy (I-131) uses radioactive iodine to destroy overactive thyroid cells or thyroid cancer remnants following surgery. This guide covers how the capsule works, clinical evidence, approximate costs in Turkey compared with the UK, US and Germany, hospital isolation protocols, radiation safety at home, potential side effects and what to ask your nuclear medicine team.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Radiotherapy & Radiosurgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Radioiodine Therapy
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Radioiodine therapy in Turkey: what it is and how I-131 works
Radioiodine therapy, also known as radioactive iodine treatment or I-131 therapy, is a targeted internal radiation treatment used primarily for differentiated thyroid cancer and benign conditions such as hyperthyroidism and toxic multinodular goitre. The treatment relies on a unique physiological mechanism: thyroid cells are virtually the only cells in the human body that absorb and concentrate iodine. When a radioactive isotope of iodine (iodine-131) is swallowed in a capsule or liquid, it enters the bloodstream and is absorbed selectively by functioning thyroid tissue. As the isotope decays, it emits beta radiation that destroys thyroid cells within a 1 to 2 millimetre radius, sparing surrounding tissues such as the parathyroid glands, vocal cord nerves and neighbouring organs. International hospitals providing radioiodine therapy in Turkey deliver this treatment within specialised nuclear medicine departments equipped with lead-shielded patient suites. For an overview of advanced cancer therapies available abroad, explore our wider guide to oncology treatments in Turkey.
Radioiodine therapy is not external radiation. It delivers radiation from inside the targeted cells, allowing clinicians to administer concentrated therapeutic doses while minimising collateral damage to healthy tissues. This guide explains what is radioiodine therapy, how the treatment is prepared and delivered, comparative costs, radiation precautions and how to plan medical travel with confidence.
How is radioiodine therapy administered?
The administration of radioiodine therapy follows a structured medical protocol overseen by a licensed nuclear medicine specialist and a medical radiation physicist. Because thyroid tissue must actively absorb the isotope, preparation begins weeks before the actual administration date. Once preparation is complete and your thyroid-stimulating hormone (TSH) level is confirmed to be sufficiently elevated, you are admitted to a dedicated lead-shielded isolation room in the hospital.
The radioactive iodine is taken orally, usually as a single gelatin capsule or occasionally as a tasteless liquid draught, swallowed with water. Ingesting the capsule takes only a few seconds. However, because your body temporarily emits gamma radiation and excretes unabsorbed radioiodine in sweat, saliva and urine, you remain in the shielded room for one to three days until radiation monitors confirm that emissions have fallen below legal public-safety thresholds. Unlike external beam methods or targeted cranial radiosurgery such as gamma knife, radioiodine therapy works systemically through metabolic uptake, allowing it to seek out microscopic thyroid remnants or distant metastases wherever functional thyroid cells exist.
Does radioiodine therapy work? What the clinical evidence shows
Extensive clinical research and guidelines from international bodies, including the American Thyroid Association (ATA), the British Thyroid Association (BTA) and the European Association of Nuclear Medicine (EANM), confirm that does radioiodine therapy work effectively for its established indications. In patients treated for differentiated thyroid cancer (papillary and follicular subtypes) who have undergone total thyroidectomy, adjuvant radioiodine ablation reliably destroys remaining normal thyroid remnants and microscopic malignant cells, significantly lowering long-term recurrence rates and facilitating post-treatment surveillance using serum thyroglobulin measurements.
For benign hyperthyroidism, including Graves' disease and toxic adenomas, a single dose of radioiodine achieves remission in over 85 to 90 per cent of patients within three to six months. However, the therapy has clear biological boundaries: it is ineffective against medullary thyroid cancer and anaplastic thyroid carcinoma, because these specific malignancies originate from non-follicular C-cells or have lost their sodium-iodide symporter transport mechanisms. Responsible clinical teams will never promise complete tumour eradication without thorough pre-treatment histology and diagnostic uptake scanning.
Radioiodine therapy cost in Turkey compared with the UK, US and Germany
The radioiodine therapy cost varies depending on whether treatment is aimed at benign hyperthyroidism or thyroid cancer ablation, which requires higher radioactivity doses and longer hospital isolation in a lead-lined suite. The figures below provide approximate ranges across different countries. These represent broad estimates rather than formal hospital quotes, and individual fees depend on dosage, isolation duration and pre-treatment preparation.
| Country | Approximate cost range |
|---|---|
| Turkey | €1,800 – €5,500 |
| United Kingdom | €4,500 – €11,500 |
| United States | €7,500 – €20,000 |
| Germany | €4,000 – €10,500 |
Several clinical variables affect the final radioiodine therapy price. Low-dose therapy for hyperthyroidism (typically 185 to 555 MBq) may be performed on an outpatient or brief stay basis depending on local regulations, keeping costs at the lower end. High-dose remnant ablation or metastatic treatment (typically 1,110 to 5,550 MBq or more) requires two to four nights in a certified isolation room with dedicated plumbing, continuous radiation physicist monitoring, pre-treatment dosimetry and a post-therapy whole-body diagnostic scan. If recombinant human TSH (rhTSH / Thyrogen) injections are used instead of thyroid hormone withdrawal, the medication cost will also be reflected in the quote. A comprehensive international treatment package in Turkey generally includes hospitalisation in a private shielded room, medical fees, nursing, radiopharmaceutical administration, post-treatment imaging and airport transfers. To request a tailored itemised estimate based on your required dosage and hospital stay, request a free quote before travelling.
Radioiodine therapy, antithyroid drugs or surgery?
When managing thyroid conditions, patients and clinicians usually choose between three primary modalities: medical antithyroid therapy, surgical excision and radioiodine ablation. Each approach has defined clinical indications, advantages and potential limitations.
| Method | Primary indication | Key advantages | Typical limitations |
|---|---|---|---|
| Radioiodine therapy (I-131) | Differentiated thyroid cancer ablation, toxic goitre, recurrent Graves' disease | Non-invasive, high definitive cure rate, targets microscopic remnants | Requires temporary radiation isolation; causes permanent hypothyroidism |
| Total or subtotal thyroidectomy | Suspicious or confirmed large tumours, obstructive goitres, severe eye disease | Immediate physical removal of tissue, rapid symptom relief | General anaesthesia risks, potential vocal cord nerve or parathyroid injury |
| Antithyroid medications | Initial treatment of hyperthyroidism, pregnancy-related thyrotoxicosis | Preserves natural thyroid gland, non-surgical, reversible | High relapse rate after discontinuation, requires long-term blood monitoring |
For differentiated thyroid malignancies, surgery and radioiodine are complementary rather than competing: surgery removes the primary tumour bulk, whereas radioiodine ablation eliminates microscopic residues. For patients with hyperthyroidism who cannot tolerate antithyroid medications or who experience disease relapse after a course of tablets, radioiodine offers a definitive non-surgical cure.
Who is a suitable candidate for radioiodine treatment?
Determining clinical suitability requires detailed endocrinological assessment, blood tests and imaging. Radioiodine therapy is typically indicated for:
- Patients with confirmed differentiated thyroid cancer (papillary, follicular or Hurthle cell carcinoma) following total thyroidectomy who exhibit intermediate or high risk of recurrence.
- Patients with differentiated thyroid cancer experiencing elevated post-surgical thyroglobulin levels or known iodine-avid distant metastases.
- Individuals with hyperthyroidism caused by Graves' disease that has recurred after antithyroid drugs or where medication causes adverse reactions.
- Patients with autonomous toxic multinodular goitre or solitary toxic adenoma causing thyrotoxicosis.
Conversely, radioiodine therapy is strictly contraindicated during pregnancy and breastfeeding, as radioactive iodine crosses the placenta and concentrates in breast milk, causing irreversible damage to the foetal or infant thyroid. Female patients must have a confirmed negative pregnancy test immediately prior to administration. The therapy is also not suitable for patients with active, moderate-to-severe Graves' orbitopathy (thyroid eye disease), as radiation release can temporarily exacerbate eye inflammation unless prophylactic corticosteroids are administered. For patients whose tumours do not absorb iodine, external radiation modalities such as tomotherapy may be considered instead.
Preparing for treatment: low-iodine diet and TSH elevation
Successful radioiodine uptake depends on rigorous preparation. If your body's cells are already saturated with dietary iodine, they will not absorb the therapeutic I-131 isotope. Therefore, patients must follow a strict low-iodine diet for one to two weeks before treatment. This involves avoiding iodised salt, seafood, kelp, dairy products, egg yolks, commercial baked goods containing iodate dough conditioners and certain red food colourings. You must also avoid iodine-containing medications and iodinated radiocontrast agents used in CT scans for at least six to eight weeks beforehand.
The second critical requirement is elevating your TSH level, which stimulates thyroid cells to express the transport channels needed to absorb iodine. This is achieved in one of two ways: thyroid hormone withdrawal (stopping levothyroxine for three to four weeks, which causes temporary fatigue, cold sensitivity and weight gain), or recombinant human TSH (rhTSH) injections. Recombinant TSH consists of two intramuscular injections given on the two consecutive days before the radioiodine dose, allowing your TSH to rise sharply without requiring you to stop daily thyroid tablets or endure hypothyroid symptoms.
Radioiodine therapy recovery, isolation rules and radiation safety
During the early phase of radioiodine therapy recovery, the main consideration is radiation safety rather than physical wound healing. After swallowing the capsule, your body excretes the excess, unbound radioactive iodine primarily through urine, with smaller amounts in saliva, sweat and bowel motions. In Turkey, patient suites in accredited hospitals are fitted with specialised lead shielding and independent waste-retention drainage systems. Nursing staff and physicians monitor your external radiation levels daily using hand-held radiation meters. Once emission falls below national regulatory thresholds—typically after 24 to 72 hours—you are officially discharged.
Following discharge, you must follow strict radiation protection rules at home or in your hotel for an additional five to seven days:
- Maintain a safe distance (at least one to two metres) from other adults, and avoid close contact with pregnant women, infants and young children.
- Sleep in a separate bedroom and use a separate bathroom whenever possible.
- Sit down to urinate to prevent splashing, and flush the toilet twice after each use.
- Wash your hands frequently with soap and water, and drink generous amounts of fluids to flush remaining radioactivity from your bladder.
- Wash your towels, bed linen and underwear separately from the laundry of other household members.
- Avoid public transport or crowded gatherings during the initial days recommended by your radiation protection officer.
Most patients feeling physically well can return to non-contact desk work after five to ten days, once formal radiation isolation rules expire.
What results can you expect from radioiodine therapy?
Unlike surgical procedures where physical tissue is altered instantly, radioiodine works gradually over several weeks and months. In cancer ablation, clinicians assess treatment success through post-therapy imaging and blood tests rather than visible physical transformations. Between two and ten days after taking the capsule, a post-therapy whole-body scintigraphy scan (often combined with SPECT/CT) is performed to document where the radioactive iodine has concentrated and confirm the absence of unexpected distant spread.
Definitive remission is evaluated six to twelve months later through neck ultrasound examinations and serum thyroglobulin (Tg) blood tests. In successful cases, thyroglobulin becomes undetectable, confirming that all thyroid tissue has been eradicated. For hyperthyroidism patients, thyroid hormone levels gradually decrease, with normal thyroid function or expected hypothyroidism appearing within three to six months. It is important to note that radioiodine cannot reverse pre-existing surgical scars or existing orbital tissue expansion from Graves' eye disease; realistic expectations focus entirely on metabolic control and cellular elimination.
Risks and side effects of radioiodine therapy
Radioiodine therapy has been used safely in clinical practice for more than seven decades and has a well-documented safety profile supported by guidance from the National Health Service (NHS), the American Thyroid Association and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Immediate, short-term side effects are generally mild to moderate. These may include temporary neck tenderness or swelling, mild nausea during the first 24 hours, altered taste perception (dysgeusia) and dry mouth caused by inflammation of the salivary glands (sialadenitis). Sucking sour sweets or lemon drops 24 hours after administration helps promote saliva flow and protect salivary ducts.
Long-term consequences include permanent hypothyroidism, which is an expected outcome of complete thyroid tissue destruction; this is safely managed with lifelong daily levothyroxine replacement tablets. In men receiving high cumulative doses for metastatic cancer, transient reductions in sperm count may occur, and sperm banking may be discussed before treatment. In women, temporary menstrual irregularities can occur, and pregnancy must be avoided for at least six to twelve months post-therapy. Although high cumulative doses carry a very small statistical risk of secondary malignancies or leukaemia, standard therapeutic doses used for remnant ablation or hyperthyroidism carry no clinically significant increase in long-term cancer mortality according to major consensus studies.
How to choose a nuclear medicine centre in Turkey and questions to ask
When selecting a hospital for radioiodine therapy Turkey, focus on the facility's nuclear medicine infrastructure and clinical accreditations. In Turkey, accredited medical centres feature modern radiopharmacy laboratories, dedicated inpatient shielded suites and advanced SPECT/CT imaging scanners. To learn how international medical travel is coordinated from medical record review to airport transfers, see how it works.
Key red flags to watch for include facilities that administer high therapeutic doses on an outpatient basis without adequate radiation retention systems, clinics that fail to provide dietary guidelines, or providers that quote prices without knowing your required radioactivity dose or pathology details. Before committing to treatment, consider asking the clinical team the following questions:
- What specific radioactivity dose (in MBq or mCi) is recommended for my condition, and how was it calculated?
- Will my preparation use recombinant human TSH (rhTSH) injections or thyroid hormone withdrawal?
- How many days will I need to remain in the lead-shielded isolation room?
- Is post-therapy whole-body SPECT/CT scanning included in the package?
- What exact radiation safety precautions must I maintain when travelling home on an aircraft?
- Who will monitor my thyroid hormone levels and liaise with my local endocrinologist after discharge?
You can submit your pathology reports, ultrasound scans and thyroid function blood tests through our free quote page to receive a comprehensive treatment plan from an accredited hospital.
Hospitals with Oncology in Turkey
Frequently asked questions
Radioiodine therapy uses a radioactive form of iodine, iodine-131, to treat overactive thyroid glands and differentiated thyroid cancer. Thyroid cells absorb the iodine from your bloodstream, and the emitted radiation destroys abnormal thyroid tissue internally while sparing surrounding organs. It is administered as a single capsule or liquid drink taken by mouth.
Yes. Radioiodine therapy is an established treatment with high clinical success. In differentiated thyroid cancer, it reliably ablates remaining thyroid remnants and lowers recurrence risk. For hyperthyroidism, such as Graves' disease or toxic nodules, a single dose cures over 85 to 90 per cent of patients, with thyroid levels normalising within three to six months.
Radioiodine therapy in Turkey typically ranges from €1,800 to €5,500, compared with €4,500 to €11,500 in the UK and up to €20,000 in the US. The exact price depends on the required radioactivity dose, the number of nights spent in a lead-lined hospital room, diagnostic scans and whether recombinant TSH injections are used.
In thyroid cancer management, success means eliminating residual thyroid tissue, reflected by undetectable thyroglobulin tumour marker levels and clear post-treatment scans within six to twelve months. For hyperthyroidism, excessive hormone production ceases, and patients transition to a normal metabolic state or expected hypothyroidism, which is easily managed with daily levothyroxine tablets.
Initial hospital isolation in a lead-lined room lasts one to three days until your radiation emission falls below statutory safety limits. Following discharge, you must follow radiation safety precautions at home for another five to seven days, including keeping a safe distance from family members, sleeping separately and washing clothes individually.
Taking the radioiodine capsule does not cause direct physical pain because it is simply swallowed with water. Over the first few days, some patients experience mild neck tenderness, salivary gland tightness, temporary nausea or altered taste. These effects are managed with standard anti-nausea tablets, simple pain relief and drinking plenty of water.
The therapeutic destruction of thyroid tissue is permanent. Once radioiodine eliminates overactive or cancerous thyroid follicular cells, those cells cannot regenerate. For cancer patients, this reduces long-term recurrence risk. For hyperthyroid patients, the permanent destruction of thyroid tissue means lifelong daily thyroid hormone tablets are usually required to maintain normal metabolism.
Radioiodine has been used safely worldwide for more than seventy years under established medical guidelines from the NHS and international thyroid associations. Because iodine concentrates specifically in the thyroid, non-target organs receive low radiation exposure. Strict isolation protocols protect family members, and cumulative long-term risks are minimal when clinical dosage protocols are followed.
Surgery physically removes thyroid tissue under general anaesthesia, carrying risks of vocal cord nerve injury or hypoparathyroidism. Radioiodine therapy is non-invasive and destroys tissue internally without surgical incisions, but requires radiation isolation and takes several months to show full effect. In thyroid cancer, surgery removes the tumour and radioiodine ablates microscopic remnants.
Most international patients stay in Turkey for five to seven days. This allows time for pre-treatment blood tests and scans, one to three nights in a specialised hospital isolation room, post-therapy imaging and a final discharge check by the nuclear medicine physician before flying home safely.
Patient stories